Published in Clin Cancer Res on January 15, 2006
Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol (2010) 1.33
Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol (2007) 0.97
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat Clin Pract Oncol (2009) 0.92
Applications of stable isotopes in clinical pharmacology. Br J Clin Pharmacol (2011) 0.87
Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients. Ther Adv Med Oncol (2013) 0.82
Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother Pharmacol (2011) 0.82
Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study. J Gastric Cancer (2015) 0.77
Clinical management of localized colon cancer with capecitabine. Clin Med Insights Oncol (2012) 0.77
Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol (2016) 0.75
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics (2003) 2.89
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods. PLoS One (2009) 2.21
Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs (2009) 1.99
Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res (2005) 1.98
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood (2008) 1.86
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther (2003) 1.86
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol (2006) 1.78
In utero exposure to bisphenol A shifts the window of susceptibility for mammary carcinogenesis in the rat. Environ Health Perspect (2010) 1.75
Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol (2003) 1.70
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn (2006) 1.70
Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. Mol Ther (2007) 1.68
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
TET1 controls CNS 5-methylcytosine hydroxylation, active DNA demethylation, gene transcription, and memory formation. Neuron (2013) 1.64
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. Sex Transm Dis (2010) 1.61
Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem (2002) 1.54
Waist circumference values are increasing beyond those expected from BMI increases. Obesity (Silver Spring) (2007) 1.54
Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up. World J Surg (2005) 1.47
Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg (2006) 1.46
Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res (2002) 1.35
Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2009) 1.34
Local and systemic cytokine levels in relation to changes in vaginal flora. J Infect Dis (2006) 1.32
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys (2008) 1.27
IFTA-2 is a conserved cilia protein involved in pathways regulating longevity and dauer formation in Caenorhabditis elegans. J Cell Sci (2006) 1.24
Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res (2013) 1.24
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol (2005) 1.23
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther (2007) 1.19
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther (2006) 1.12
Predictors of bacterial vaginosis in adolescent women who douche. Sex Transm Dis (2004) 1.12
Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol (2011) 1.11
Predicting fluorouracil toxicity: can we finally do it? J Clin Oncol (2008) 1.08
Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clin Infect Dis (2003) 1.08
The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc (2010) 1.08
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. Clin Adv Hematol Oncol (2004) 1.07
Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res (2012) 1.07
Aripiprazole (Otsuka Pharmaceutical Co). Curr Opin Investig Drugs (2002) 1.06
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res (2005) 1.04
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J (2007) 1.04
DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol (2006) 1.02
Light-intensity activity attenuates functional decline in older cancer survivors. Med Sci Sports Exerc (2014) 1.02
Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics (2002) 1.01
High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.01
Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines. Otolaryngol Head Neck Surg (2007) 1.00
Peripheral neuropathy associated with capecitabine. Anticancer Drugs (2004) 0.99
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res (2004) 0.99
Partnership concurrency status and condom use among women diagnosed with Trichomonas vaginalis. Womens Health Issues (2008) 0.99
Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob Agents Chemother (2012) 0.99
Factors associated with intention to vaccinate a daughter against HPV: a statewide survey in Alabama. J Pediatr Adolesc Gynecol (2011) 0.98
Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res (2014) 0.98
Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea. J Clin Microbiol (2002) 0.98
Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer. Laryngoscope (2010) 0.97
Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.97
Effect of diet with and without exercise training on markers of inflammation and fat distribution in overweight women. Obesity (Silver Spring) (2010) 0.96
Predisposing factors for self-inflicted burns. J Burn Care Rehabil (2003) 0.95
Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). J Neurooncol (2006) 0.94
The impact of cost on the availability of fruits and vegetables in the homes of schoolchildren in Birmingham, Alabama. Am J Public Health (2006) 0.94
Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol (2012) 0.93
Outcomes following temporal bone resection. Laryngoscope (2010) 0.93
Comparison of inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey, and rat hepatocytes. Drug Metab Pharmacokinet (2007) 0.93
Detection of nevirapine in plasma using thin-layer chromatography. J Acquir Immune Defic Syndr (2004) 0.93
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol (2002) 0.92
Induction of NQO1 in cancer cells. Methods Enzymol (2004) 0.92
Association of Mobiluncus curtisii with recurrence of bacterial vaginosis. Sex Transm Dis (2008) 0.91
Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum Gene Ther (2002) 0.91
Gli1 promotes cell survival and is predictive of a poor outcome in ERalpha-negative breast cancer. Breast Cancer Res Treat (2009) 0.91
The clinical case for proton beam therapy. Radiat Oncol (2012) 0.90
Telomere dynamics in rhesus monkeys: no apparent effect of caloric restriction. J Gerontol A Biol Sci Med Sci (2011) 0.90
Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? Support Cancer Ther (2007) 0.89
Inclusion of complementary and alternative medicine in US state comprehensive cancer control plans: baseline data. J Cancer Educ (2009) 0.89
Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS. Clin Endocrinol (Oxf) (2013) 0.89
microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther (2014) 0.89
Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics (2007) 0.88
Management of the N0 neck in recurrent laryngeal squamous cell carcinoma. Laryngoscope (2010) 0.88
Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol Cancer Ther (2007) 0.88
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity. J Gene Med (2007) 0.88
Markers of inflammation and fat distribution following weight loss in African-American and white women. Obesity (Silver Spring) (2011) 0.88
Identification of a novel percent mammographic density locus at 12q24. Hum Mol Genet (2012) 0.88
Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.88
Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product. Free Radic Res (2004) 0.87
A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res (2010) 0.87
A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem (2002) 0.87
Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol (2007) 0.87
Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential. Cancer Gene Ther (2003) 0.87
Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics (2008) 0.86
Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe. Br J Clin Pharmacol (2005) 0.86
Ubiquitous Brms1 expression is critical for mammary carcinoma metastasis suppression via promotion of apoptosis. Clin Exp Metastasis (2012) 0.86
Self-efficacy as a predictor of weight change and behavior change in the PREMIER trial. J Nutr Educ Behav (2013) 0.86
Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet (2012) 0.86
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther (2002) 0.85